Search by name

Enter the drug you want to search for...


Information about interaction with CYP3A1
STRONG INHIBITOR MODERATE INHIBITOR WEAK INHIBITOR STRONG INDUCTOR MODERATE INDUCTOR WEAK INDUCTOR
Effect on the sensitive index substrate (SS) SS AUC increases 5 times SS AUC increases from ≥2 to <5 times SS AUC increases from ≥1.25 to <2 times SS AUC decreases ≥80% SS AUC decreases from ≥50% to <80% SS AUC decreases from ≥20% to <50%
Clinical significance Toxicity monitoring Low risk of DDI Low risk of DDI Efficacy monitoring Efficacy monitoring Low risk of DDI
Recommendations Consider lowering the substrate dose Monitoring None Consider increasing the sustrate dose Monitoring None
AUC: area under the curve; DDI: drug-drug interaction.
1. Bellet M, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol. 2019 May 10;11:1758835919833867. doi: 10.1177/1758835919833867.